Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lakcid
- Development stage
- Unknown
- Lead developer
- Synthaverse
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lakcid is a probiotic medicinal product developed by the Polish pharmaceutical company Synthaverse (formerly Biomed-Lublin). It contains lyophilized live bacteria of the strain *Lactobacillus rhamnosus* (specifically strains Pen, E/N, and Oxy). The product is designed to colonize the intestinal mucosa, thereby restoring and normalizing the composition of the gastrointestinal microflora. It is primarily indicated for the treatment and prevention of intestinal dysbiosis, particularly following antibiotic therapy that may sterilize or disrupt the natural gut microbiota. Produced since 1959, Lakcid is registered as a medicinal product (OTC drug) in Poland and is marketed internationally in various formulations, including Lakcid Forte, which contains a higher concentration of probiotic bacteria.
- Brand names
- LakcidLakcid ForteLakcid L
- Other names
- Lactobacillus rhamnosus probiotic
Beyond the preview
Go deeper on Lakcid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lakcid.